Kinetin Circadian Modulation for Jet Lag and Shift-Work Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for circadian rhythm disorders, such as bright light therapy and melatonin, are inconvenient, ineffective for certain conditions, and lack direct molecular targeting, leading to variable responses and potential side effects.
Innovation Solution
N-(furan-2-ylmethyl)-7H-purin-6-amine (kinetin) modulates circadian rhythms by influencing the activity and concentration of molecular components of the mammalian circadian oscillator, allowing for precise modulation of amplitude, period, and phase.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bright light therapy is used to treat circadian rhythm disorders, then circadian rhythms can be reset, but the treatment is inconvenient and requires precise timing
Solution Approach 1:
The patent replaces the mechanical/physical system of bright light exposure with a chemical system - using melatonin and its derivatives as pharmacological agents to reset circadian rhythms. This substitution eliminates the need for precise timing and special equipment, allowing oral administration at convenient times while achieving the same therapeutic goal of circadian rhythm resetting
Solution Approach 2:
The patent changes the parameter of treatment delivery from external physical stimulus (light intensity and duration) to internal chemical modulation (melatonin dosage and timing). By administering melatonin at specific dosages and times, the treatment achieves circadian rhythm resetting without requiring the precise timing constraints of light therapy, thus improving ease of operation while maintaining reliability
2Reliability
If melatonin is used to treat circadian rhythm disorders, then circadian rhythms can be modulated, but responses vary between individuals and side effects occur
Solution Approach 1:
The patent develops extended-release formulations of melatonin that deliver the drug at different rates and times in different regions of the gastrointestinal tract. This creates localized, controlled release patterns that maintain steady plasma concentrations, reducing individual variability in response and minimizing side effects while achieving reliable circadian rhythm modulation
Solution Approach 2:
The patent uses controlled-release mechanisms that deliver melatonin in periodic pulses over an extended period (8-12 hours), rather than as a single bolus dose. This periodic delivery mimics the natural circadian pattern of melatonin secretion, improving therapeutic effectiveness while reducing peak-related side effects and inter-individual variability
3Reliability
If current circadian rhythm treatments are used, then some symptomatic relief is achieved, but they lack direct molecular targeting
Solution Approach 1:
The patent uses melatonin and its derivatives as chemical intermediaries that directly interact with circadian rhythm regulatory pathways. These compounds serve as mediators between external treatment and internal circadian clock mechanisms, providing more precise molecular targeting compared to non-specific approaches while maintaining the reliability of symptomatic relief
Data Source
AI summary
N-(furan-2-ylmethyl)-7H-purin-6-amine, or a pharmaceutically acceptable salt or solvate thereof, for prevention and/or treatment of circadian rhythm disorders, circadian rhythm diseases and/or circadian rhythm dysfunctions is disclosed. The disorders, diseases and dysfunctions include, inter alia, jet-lag, social jet-lag, shift-work disorder, and circadian rhythm disturbance induced by neurodegeneration is also disclosed.